Critical

Duct-dependent congenital heart disease presenting as neonatal collapse (critical CHD; ductal-dependent lesions)

Neonatal cardiac emergency · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Collapse or cyanosis in the first days-weeks of life as the ductus arteriosus closes. Duct-dependent systemic circulation (e.g. hypoplastic left heart, critical coarctation, interrupted arch, critical aortic stenosis) causes shock/poor perfusion; duct-dependent pulmonary circulation (e.g. pulmonary atresia, critical pulmonary stenosis, severe tetralogy, transposition) causes profound cyanosis. Prostaglandin reopens/maintains the duct and is life-saving.

Red flags

  • Shock/poor perfusion, weak or absent femoral pulses (coarctation/arch obstruction)
  • Profound cyanosis not correcting with oxygen (hyperoxia test failure)
  • Pre-/post-ductal saturation difference
  • Metabolic acidosis / rising lactate
  • Collapse coinciding with physiological duct closure (day 2 to ~2 weeks)
  • Apnoea after starting prostaglandin

Assessment

Differential diagnosis

  • Neonatal sepsis
  • Inborn error of metabolism (acidosis, hypoglycaemia)
  • Hypovolaemia/haemorrhage
  • Non-accidental injury
  • Severe respiratory disease (RDS, pneumonia, PPHN)
  • Arrhythmia (SVT)

Investigations

  • Pre- and post-ductal SpO2 (difference suggests duct-dependent/coarctation); 4-limb BP
  • Hyperoxia test (fails to correct cyanosis in cardiac cause)
  • Blood gas/lactate (metabolic acidosis), glucose, FBC, blood culture, U&E
  • CXR (heart size, pulmonary vascularity), ECG
  • Urgent echocardiography - definitive; do not delay prostaglandin while awaiting it if strongly suspected

Management

  • Resuscitate ABC: airway/oxygen cautiously (high FiO2 can worsen duct-dependent systemic lesions by promoting ductal closure/pulmonary overcirculation)
  • Start IV prostaglandin E1 (alprostadil/dinoprostone) immediately if duct-dependent lesion suspected - do not wait for echo
  • Secure reliable IV/UVC access; obtain blood gas, glucose, cultures; treat hypoglycaemia and acidosis
  • Give empirical antibiotics as sepsis cannot be excluded
  • Prepare to intubate/ventilate - prostaglandin causes apnoea and the neonate often needs transfer
  • Urgent discussion with paediatric cardiology and retrieval/transfer to a cardiac centre

Drugs & doses

Prostaglandin E1 (alprostadil) IV infusion: start ~10 nanogram/kg/min (range 5-50); use higher starting dose (>10, up to 50-100 ng/kg/min) in a collapsed/'grey' or profoundly cyanosed baby to reopen the duct; titrate down to maintenance 3-20 ng/kg/min once stable [verify local]
Be prepared for apnoea, hypotension and flushing - have intubation ready, especially at higher doses
10% glucose 2 mL/kg IV for hypoglycaemia, then maintenance infusion
0.9% saline 10 mL/kg IV cautious bolus for shock, reassess (avoid fluid overload)
Empirical IV antibiotics (benzylpenicillin + gentamicin) as sepsis mimic [verify local]

Disposition

Admit to neonatal/paediatric intensive care; urgent paediatric cardiology referral and transfer to a cardiac surgical centre on prostaglandin.

Complications & pitfalls

  • Cardiogenic shock, cardiac arrest, death
  • Prostaglandin side effects: apnoea, hypotension, fever, flushing
  • End-organ injury (renal, cerebral, necrotising enterocolitis) from hypoperfusion

Exam pearls

  • A collapsed or deeply cyanosed neonate in the first weeks = suspect duct-dependent CHD; start prostaglandin without waiting for echo
  • Check pre- and post-ductal saturations and femoral pulses in every unwell neonate
  • Avoid high FiO2 in suspected duct-dependent systemic circulation - it can accelerate ductal closure and worsen the baby
  • Always anticipate apnoea on prostaglandin - prepare airway/ventilation before/while starting
  • Treat empirically for sepsis in parallel - the two are indistinguishable at the bedside

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.